|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AXIN2 |
Gene summary for AXIN2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AXIN2 | Gene ID | 8313 |
| Gene name | axin 2 | |
| Gene Alias | AXIL | |
| Cytomap | 17q24.1 | |
| Gene Type | protein-coding | GO ID | GO:0000819 | UniProtAcc | Q9Y2T1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8313 | AXIN2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.69e-04 | 1.96e-01 | 0.0155 |
| 8313 | AXIN2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 6.32e-11 | 5.25e-01 | -0.0811 |
| 8313 | AXIN2 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.73e-04 | 3.47e-01 | -0.1088 |
| 8313 | AXIN2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 5.22e-06 | 5.39e-01 | -0.059 |
| 8313 | AXIN2 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.41e-25 | 8.04e-01 | 0.096 |
| 8313 | AXIN2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.52e-04 | 5.36e-01 | 0.0338 |
| 8313 | AXIN2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.09e-25 | 7.26e-01 | 0.0674 |
| 8313 | AXIN2 | HTA11_6818_2000001011 | Human | Colorectum | AD | 2.70e-02 | 2.60e-01 | 0.0112 |
| 8313 | AXIN2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 9.79e-08 | 4.53e-01 | 0.0588 |
| 8313 | AXIN2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.33e-18 | 5.98e-01 | 0.294 |
| 8313 | AXIN2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.28e-07 | 4.35e-01 | 0.3859 |
| 8313 | AXIN2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.19e-10 | 7.48e-01 | 0.2585 |
| 8313 | AXIN2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 9.62e-19 | 6.31e-01 | 0.3005 |
| 8313 | AXIN2 | A015-C-203 | Human | Colorectum | FAP | 7.28e-10 | 6.56e-01 | -0.1294 |
| 8313 | AXIN2 | A002-C-201 | Human | Colorectum | FAP | 4.10e-03 | 4.16e-01 | 0.0324 |
| 8313 | AXIN2 | A001-C-119 | Human | Colorectum | FAP | 4.52e-16 | 8.81e-01 | -0.1557 |
| 8313 | AXIN2 | A001-C-108 | Human | Colorectum | FAP | 4.60e-11 | 6.08e-01 | -0.0272 |
| 8313 | AXIN2 | A002-C-021 | Human | Colorectum | FAP | 1.00e-26 | 7.13e-01 | 0.1171 |
| 8313 | AXIN2 | A002-C-205 | Human | Colorectum | FAP | 1.84e-20 | 8.43e-01 | -0.1236 |
| 8313 | AXIN2 | A001-C-104 | Human | Colorectum | FAP | 8.82e-11 | 5.50e-01 | 0.0184 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
| GO:0009895 | Colorectum | AD | negative regulation of catabolic process | 124/3918 | 320/18723 | 1.66e-13 | 3.35e-11 | 124 |
| GO:0031330 | Colorectum | AD | negative regulation of cellular catabolic process | 104/3918 | 262/18723 | 2.66e-12 | 3.96e-10 | 104 |
| GO:0006401 | Colorectum | AD | RNA catabolic process | 102/3918 | 278/18723 | 8.64e-10 | 6.76e-08 | 102 |
| GO:0044270 | Colorectum | AD | cellular nitrogen compound catabolic process | 147/3918 | 451/18723 | 3.35e-09 | 2.23e-07 | 147 |
| GO:0046700 | Colorectum | AD | heterocycle catabolic process | 145/3918 | 445/18723 | 4.37e-09 | 2.84e-07 | 145 |
| GO:0006402 | Colorectum | AD | mRNA catabolic process | 87/3918 | 232/18723 | 4.40e-09 | 2.84e-07 | 87 |
| GO:0034655 | Colorectum | AD | nucleobase-containing compound catabolic process | 133/3918 | 407/18723 | 1.56e-08 | 9.12e-07 | 133 |
| GO:0019439 | Colorectum | AD | aromatic compound catabolic process | 146/3918 | 467/18723 | 7.48e-08 | 3.84e-06 | 146 |
| GO:1901361 | Colorectum | AD | organic cyclic compound catabolic process | 153/3918 | 495/18723 | 8.23e-08 | 4.18e-06 | 153 |
| GO:0061013 | Colorectum | AD | regulation of mRNA catabolic process | 64/3918 | 166/18723 | 1.44e-07 | 6.59e-06 | 64 |
| GO:0051052 | Colorectum | AD | regulation of DNA metabolic process | 116/3918 | 359/18723 | 2.47e-07 | 1.00e-05 | 116 |
| GO:0043487 | Colorectum | AD | regulation of RNA stability | 63/3918 | 170/18723 | 9.17e-07 | 3.12e-05 | 63 |
| GO:0043488 | Colorectum | AD | regulation of mRNA stability | 59/3918 | 158/18723 | 1.50e-06 | 4.66e-05 | 59 |
| GO:0030111 | Colorectum | AD | regulation of Wnt signaling pathway | 102/3918 | 328/18723 | 8.51e-06 | 2.03e-04 | 102 |
| GO:0016055 | Colorectum | AD | Wnt signaling pathway | 130/3918 | 444/18723 | 1.60e-05 | 3.37e-04 | 130 |
| GO:1903312 | Colorectum | AD | negative regulation of mRNA metabolic process | 37/3918 | 92/18723 | 1.95e-05 | 4.01e-04 | 37 |
| GO:0198738 | Colorectum | AD | cell-cell signaling by wnt | 130/3918 | 446/18723 | 2.02e-05 | 4.10e-04 | 130 |
| GO:2001020 | Colorectum | AD | regulation of response to DNA damage stimulus | 71/3918 | 219/18723 | 4.38e-05 | 7.65e-04 | 71 |
| GO:1902369 | Colorectum | AD | negative regulation of RNA catabolic process | 30/3918 | 75/18723 | 1.30e-04 | 1.87e-03 | 30 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
| hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa05225 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
| hsa04310 | Colorectum | AD | Wnt signaling pathway | 56/2092 | 171/8465 | 1.03e-02 | 3.93e-02 | 2.51e-02 | 56 |
| hsa050101 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
| hsa050221 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa052251 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
| hsa043101 | Colorectum | AD | Wnt signaling pathway | 56/2092 | 171/8465 | 1.03e-02 | 3.93e-02 | 2.51e-02 | 56 |
| hsa050104 | Colorectum | MSS | Alzheimer disease | 169/1875 | 384/8465 | 1.21e-22 | 1.01e-20 | 6.21e-21 | 169 |
| hsa050224 | Colorectum | MSS | Pathways of neurodegeneration - multiple diseases | 192/1875 | 476/8465 | 2.79e-20 | 1.04e-18 | 6.36e-19 | 192 |
| hsa052102 | Colorectum | MSS | Colorectal cancer | 36/1875 | 86/8465 | 3.08e-05 | 3.22e-04 | 1.97e-04 | 36 |
| hsa052134 | Colorectum | MSS | Endometrial cancer | 27/1875 | 58/8465 | 3.18e-05 | 3.23e-04 | 1.98e-04 | 27 |
| hsa052252 | Colorectum | MSS | Hepatocellular carcinoma | 56/1875 | 168/8465 | 5.04e-04 | 3.45e-03 | 2.11e-03 | 56 |
| hsa043102 | Colorectum | MSS | Wnt signaling pathway | 53/1875 | 171/8465 | 4.24e-03 | 1.86e-02 | 1.14e-02 | 53 |
| hsa04390 | Colorectum | MSS | Hippo signaling pathway | 48/1875 | 157/8465 | 8.32e-03 | 3.10e-02 | 1.90e-02 | 48 |
| hsa050105 | Colorectum | MSS | Alzheimer disease | 169/1875 | 384/8465 | 1.21e-22 | 1.01e-20 | 6.21e-21 | 169 |
| hsa050225 | Colorectum | MSS | Pathways of neurodegeneration - multiple diseases | 192/1875 | 476/8465 | 2.79e-20 | 1.04e-18 | 6.36e-19 | 192 |
| hsa052103 | Colorectum | MSS | Colorectal cancer | 36/1875 | 86/8465 | 3.08e-05 | 3.22e-04 | 1.97e-04 | 36 |
| hsa052135 | Colorectum | MSS | Endometrial cancer | 27/1875 | 58/8465 | 3.18e-05 | 3.23e-04 | 1.98e-04 | 27 |
| hsa052253 | Colorectum | MSS | Hepatocellular carcinoma | 56/1875 | 168/8465 | 5.04e-04 | 3.45e-03 | 2.11e-03 | 56 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AXIN2 | SNV | Missense_Mutation | c.531N>C | p.Glu177Asp | p.E177D | Q9Y2T1 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-A1-A0SN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | ac | SD | |
| AXIN2 | SNV | Missense_Mutation | rs367697282 | c.1478N>T | p.Ser493Leu | p.S493L | Q9Y2T1 | protein_coding | tolerated(0.7) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| AXIN2 | SNV | Missense_Mutation | c.52N>T | p.Arg18Cys | p.R18C | Q9Y2T1 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| AXIN2 | SNV | Missense_Mutation | c.514N>C | p.Asp172His | p.D172H | Q9Y2T1 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-D8-A1JC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| AXIN2 | SNV | Missense_Mutation | rs372513593 | c.1483N>A | p.Gly495Ser | p.G495S | Q9Y2T1 | protein_coding | tolerated(0.25) | benign(0.003) | TCGA-E9-A244-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| AXIN2 | SNV | Missense_Mutation | c.1829N>T | p.Arg610Leu | p.R610L | Q9Y2T1 | protein_coding | tolerated(0.39) | benign(0) | TCGA-EW-A6S9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| AXIN2 | insertion | In_Frame_Ins | novel | c.1537_1538insGAT | p.His513delinsArgTyr | p.H513delinsRY | Q9Y2T1 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| AXIN2 | insertion | Frame_Shift_Ins | novel | c.1535_1536insCCACCCCCCGTGCCCACCTGTTCACCCAGGACCCT | p.Lys512AsnfsTer189 | p.K512Nfs*189 | Q9Y2T1 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| AXIN2 | SNV | Missense_Mutation | c.386N>A | p.Arg129Gln | p.R129Q | Q9Y2T1 | protein_coding | deleterious(0) | probably_damaging(0.94) | TCGA-C5-A1M8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| AXIN2 | SNV | Missense_Mutation | novel | c.1870N>A | p.Leu624Met | p.L624M | Q9Y2T1 | protein_coding | tolerated(0.47) | benign(0.377) | TCGA-EK-A2GZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8313 | AXIN2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | Platinum compounds | 24980784 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |